Ampio Picks Ascendia Pharmaceuticals To Provide CDMO Services To Support Clinical Development Of OA-201
Portfolio Pulse from Benzinga Newsdesk
Ampio Pharmaceuticals has chosen Ascendia Pharmaceuticals to provide CDMO services to support the clinical development of OA-201. This partnership is expected to accelerate the development and potential commercialization of OA-201.
October 05, 2023 | 8:46 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Ampio Pharmaceuticals' partnership with Ascendia Pharmaceuticals for CDMO services could potentially speed up the development and commercialization of OA-201, which may positively impact the company's stock.
The partnership with Ascendia Pharmaceuticals is expected to expedite the development of OA-201, which could lead to earlier commercialization and revenue generation. This could positively impact Ampio Pharmaceuticals' financial performance and, consequently, its stock price.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100